Galmed Pharmaceuticals Ltd. (GLMD) Form 6-K — May 14, 2026
Galmed Pharmaceuticals Ltd. announced significant results from a Phase 1 pharmacokinetics study of its oral formulation of Aramchol meglumine (AM). The study demonstrated that a 400mg dose of AM increases bioavailability by approximately 500% compared to a 300mg dose of Aramchol free acid (AA) administered twice daily. This advancement is pivotal for the company's transition to a once-daily lower dose, which could improve patient compliance and reduce costs.
Key figures
- Bioavailability increase
- 500%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.